FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3134964955> ?p ?o ?g. }

• W3134964955 abstract "Background: Recently, there has been a growing interest in applying immune checkpoint blockers (ICBs), so far used to treat cancer, to patients with bacterial sepsis. We aimed to develop a method for predicting the personal benefit of potential treatments for sepsis, and to apply it to therapy by meropenem, an antibiotic drug, and nivolumab, a programmed cell death-1 (PD-1) pathway inhibitor. Methods: We defined an optimization problem as a concise framework of treatment aims and formulated a fitness function for grading sepsis treatments according to their success in accomplishing the pre-defined aims. We developed a mathematical model for the interactions between the pathogen, the cellular immune system and the drugs, whose simulations under diverse combined meropenem and nivolumab schedules, and calculation of the fitness function for each schedule served to plot the fitness landscapes for each set of treatments and personal patient parameters. Results: Results show that treatment by meropenem and nivolumab has maximum benefit if the interval between the onset of the two drugs does not exceed a dose-dependent threshold, beyond which the benefit drops sharply. However, a second nivolumab application, within 7–10 days after the first, can extinguish a pathogen which the first nivolumab application failed to remove. The utility of increasing nivolumab total dose above 6 mg/kg is contingent on the patient's personal immune attributes, notably, the reinvigoration rate of exhausted CTLs and the overall suppression rates of functional CTLs. A baseline pathogen load, higher than 5,000 CFU/μL, precludes successful nivolumab and meropenem combination therapy, whereas when the initial load is lower than 3,000 CFU/μL, meropenem monotherapy suffices for removing the pathogen. Discussion: Our study shows that early administration of nivolumab, 6 mg/kg, in combination with antibiotics, can alleviate bacterial sepsis in cases where antibiotics alone are insufficient and the initial pathogen load is not too high. The study pinpoints the role of precision medicine in sepsis, suggesting that personalized therapy by ICBs can improve pathogen elimination and dampen immunosuppression. Our results highlight the importance in using reliable markers for classifying patients according to their predicted response and provides a valuable tool in personalizing the drug regimens for patients with sepsis." @default.
• W3134964955 created "2021-03-15" @default.
• W3134964955 creator A5019352016 @default.
• W3134964955 creator A5029011185 @default.
• W3134964955 creator A5058008880 @default.
• W3134964955 date "2021-03-01" @default.
• W3134964955 modified "2023-09-25" @default.
• W3134964955 title "A New Method for Optimizing Sepsis Therapy by Nivolumab and Meropenem Combination: Importance of Early Intervention and CTL Reinvigoration Rate as a Response Marker" @default.
• W3134964955 cites W1586011800 @default.
• W3134964955 cites W1735197745 @default.
• W3134964955 cites W1910012553 @default.
• W3134964955 cites W1955799584 @default.
• W3134964955 cites W1976646654 @default.
• W3134964955 cites W1977905227 @default.
• W3134964955 cites W1981774675 @default.
• W3134964955 cites W1998427452 @default.
• W3134964955 cites W2034591306 @default.
• W3134964955 cites W2040625602 @default.
• W3134964955 cites W2042347949 @default.
• W3134964955 cites W2048674276 @default.
• W3134964955 cites W2066671159 @default.
• W3134964955 cites W2075259252 @default.
• W3134964955 cites W2083513831 @default.
• W3134964955 cites W2091693435 @default.
• W3134964955 cites W2095833414 @default.
• W3134964955 cites W2097476575 @default.
• W3134964955 cites W2112121482 @default.
• W3134964955 cites W2126327450 @default.
• W3134964955 cites W2127833097 @default.
• W3134964955 cites W2135190942 @default.
• W3134964955 cites W2140938722 @default.
• W3134964955 cites W2155464214 @default.
• W3134964955 cites W2157262071 @default.
• W3134964955 cites W2157758657 @default.
• W3134964955 cites W2161227853 @default.
• W3134964955 cites W2183144139 @default.
• W3134964955 cites W2223946157 @default.
• W3134964955 cites W2280404143 @default.
• W3134964955 cites W2301209689 @default.
• W3134964955 cites W2326936967 @default.
• W3134964955 cites W2395437150 @default.
• W3134964955 cites W2507840163 @default.
• W3134964955 cites W2519164957 @default.
• W3134964955 cites W2541574334 @default.
• W3134964955 cites W2548025601 @default.
• W3134964955 cites W2605630275 @default.
• W3134964955 cites W2608823051 @default.
• W3134964955 cites W2618943818 @default.
• W3134964955 cites W2748412033 @default.
• W3134964955 cites W2770395397 @default.
• W3134964955 cites W2787399901 @default.
• W3134964955 cites W2790197442 @default.
• W3134964955 cites W2796233583 @default.
• W3134964955 cites W2887137726 @default.
• W3134964955 cites W2887577080 @default.
• W3134964955 cites W2888993305 @default.
• W3134964955 cites W2894422883 @default.
• W3134964955 cites W2900474461 @default.
• W3134964955 cites W2901619788 @default.
• W3134964955 cites W2910079519 @default.
• W3134964955 cites W2936896545 @default.
• W3134964955 cites W2939377655 @default.
• W3134964955 cites W2945590213 @default.
• W3134964955 cites W2950204168 @default.
• W3134964955 cites W2961584252 @default.
• W3134964955 cites W2972847338 @default.
• W3134964955 cites W2977556556 @default.
• W3134964955 cites W2977742973 @default.
• W3134964955 cites W2980512568 @default.
• W3134964955 cites W2998485254 @default.
• W3134964955 cites W2998853022 @default.
• W3134964955 cites W3014004967 @default.
• W3134964955 cites W3016829704 @default.
• W3134964955 cites W4206245764 @default.
• W3134964955 cites W4211253912 @default.
• W3134964955 cites W4239396218 @default.
• W3134964955 doi "https://doi.org/10.3389/fimmu.2021.616881" @default.
• W3134964955 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7959825" @default.
• W3134964955 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33732241" @default.
• W3134964955 hasPublicationYear "2021" @default.
• W3134964955 type Work @default.
• W3134964955 sameAs 3134964955 @default.
• W3134964955 citedByCount "2" @default.
• W3134964955 countsByYear W31349649552023 @default.
• W3134964955 crossrefType "journal-article" @default.
• W3134964955 hasAuthorship W3134964955A5019352016 @default.
• W3134964955 hasAuthorship W3134964955A5029011185 @default.
• W3134964955 hasAuthorship W3134964955A5058008880 @default.
• W3134964955 hasBestOaLocation W31349649551 @default.
• W3134964955 hasConcept C143998085 @default.
• W3134964955 hasConcept C203014093 @default.
• W3134964955 hasConcept C2777701055 @default.
• W3134964955 hasConcept C2779375183 @default.
• W3134964955 hasConcept C2780030458 @default.
• W3134964955 hasConcept C501593827 @default.
• W3134964955 hasConcept C71924100 @default.
• W3134964955 hasConcept C86803240 @default.
• W3134964955 hasConcept C8891405 @default.
• W3134964955 hasConcept C89423630 @default.
• W3134964955 hasConcept C94665300 @default.

• next